Literature DB >> 33432708

Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations.

Livia Guadagnoli1,2, Rena Yadlapati3, Tiffany Taft1, John E Pandolfino1, Michael Tye4, Laurie Keefer5.   

Abstract

BACKGROUND: There is a need to identify factors outside of abnormal reflux that contribute to gastroesophageal reflux disease (GERD). Esophageal hypervigilance is a psychological process impacting symptom experience in esophageal disease. However, little is known about the presence of hypervigilance in GERD phenotypes, especially in those with abnormal acid exposure or symptom index scores. The primary aim was to assess differences in self-reported esophageal hypervigilance across different GERD presentations. The secondary aim was to evaluate esophageal hypervigilance as a predictor of symptom severity.
METHODS: We conducted retrospective data analyses on a cohort of adult patients with reflux symptoms that underwent 96-hour wireless pH monitoring from 9/2015 to 9/2017. Patients were stratified into groups based on the number of days they exhibited positive acid exposure time (AET; 0 days, 1-2 days, 3+ days), and symptom index scores (SI; 0 days, 1-day, 2+ days). Esophageal hypervigilance and anxiety, and symptom frequency and severity were assessed between groups. KEY
RESULTS: A total of 123 AET cases and 116 SI cases were included for analysis. Esophageal hypervigilance and anxiety scores did not significantly differ based on the number of days of positive AET (p = 0.311) or SI (p = 0.118). Symptom severity and perceived symptom frequency differed between groups. Hypervigilance significantly predicted symptom severity, when controlling for symptom-specific anxiety.
CONCLUSIONS: Esophageal hypervigilance is persistent across patients with reflux, irrespective of acid burden and symptom index, and significantly predicts symptom severity. Hypervigilance should be considered as an independent factor contributing to esophageal symptom perception.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  anxiety; behavioral medicine; gastroesophageal reflux; psychological stress

Mesh:

Year:  2021        PMID: 33432708      PMCID: PMC8272741          DOI: 10.1111/nmo.14081

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.960


  30 in total

1.  Role of a health psychologist in the management of functional esophageal complaints.

Authors:  M E Riehl; S Kinsinger; P J Kahrilas; J E Pandolfino; L Keefer
Journal:  Dis Esophagus       Date:  2014-04-03       Impact factor: 3.429

2.  Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn.

Authors:  M E Riehl; J E Pandolfino; O S Palsson; L Keefer
Journal:  Dis Esophagus       Date:  2015-03-30       Impact factor: 3.429

3.  Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease.

Authors:  T H Taft; J R Triggs; D A Carlson; L Guadagnoli; K N Tomasino; L Keefer; J E Pandolfino
Journal:  Aliment Pharmacol Ther       Date:  2018-03-12       Impact factor: 8.171

Review 4.  Pathophysiology of Gastroesophageal Reflux Disease.

Authors:  Jan Tack; John E Pandolfino
Journal:  Gastroenterology       Date:  2017-10-14       Impact factor: 22.682

Review 5.  Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet.

Authors:  David A Katzka; John E Pandolfino; Peter J Kahrilas
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-15       Impact factor: 11.382

6.  Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.

Authors:  S Roman; L Keefer; H Imam; P Korrapati; B Mogni; K Eident; L Friesen; P J Kahrilas; Z Martinovich; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2015-09-04       Impact factor: 3.598

7.  Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care.

Authors:  R Jones; O Junghard; J Dent; N Vakil; K Halling; B Wernersson; T Lind
Journal:  Aliment Pharmacol Ther       Date:  2009-09-08       Impact factor: 8.171

8.  Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease.

Authors:  Jacqueline Lee; Angela Anggiansah; Roy Anggiansah; Alasdair Young; Terry Wong; Mark Fox
Journal:  Clin Gastroenterol Hepatol       Date:  2007-11-01       Impact factor: 11.382

9.  Esophageal Hypervigilance and Visceral Anxiety Are Contributors to Symptom Severity Among Patients Evaluated With High-Resolution Esophageal Manometry.

Authors:  Dustin A Carlson; C Prakash Gyawali; Sabine Roman; Marcelo Vela; Tiffany H Taft; Michael D Crowell; Karthik Ravi; Joseph R Triggs; Farhan Quader; Jacqueline Prescott; Frederick T J Lin; Francois Mion; Dario Biasutto; Laurie Keefer; Peter J Kahrilas; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2020-03       Impact factor: 12.045

10.  The Effect of Acute Stress on Esophageal Motility and Gastroesophageal Reflux in Healthy Humans.

Authors:  Hong Sub Lee; Chung Kyun Noh; Kwang Jae Lee
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

View more
  3 in total

Review 1.  Improving Patient Adherence to Lifestyle Changes for the Management of Gastroesophageal Reflux.

Authors:  Livia Guadagnoli; Madison Simons; Josie McGarva; Tiffany H Taft; Miranda A L van Tilburg
Journal:  Patient Prefer Adherence       Date:  2022-04-05       Impact factor: 2.711

Review 2.  Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI "resistance" - a multidisciplinary perspective.

Authors:  A Pali S Hungin; Carmelo Scarpignato; Laurie Keefer; Maura Corsetti; Foteini Anastasiou; Jean W M Muris; Juan M Mendive; Peter J Kahrilas
Journal:  Aliment Pharmacol Ther       Date:  2022-04-22       Impact factor: 9.524

3.  Esophageal Hypervigilance and Symptom-Specific Anxiety in Patients with Eosinophilic Esophagitis.

Authors:  Tiffany H Taft; Dustin A Carlson; Madison Simons; Sonia Zavala; Ikuo Hirano; Nirmala Gonsalves; John E Pandolfino
Journal:  Gastroenterology       Date:  2021-06-19       Impact factor: 33.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.